Surgical resection after gefitinib treatment in patients with lung adenocarcinoma harboring epidermal growth factor receptor gene mutation
Surgical resection after gefitinib treatment in patients with lung adenocarcinoma harboring epidermal growth factor receptor gene mutation
复制标题
DOI：
10.1016/j.lungcan.2007.04.016
复制
发表时间：
2007-10-01
期刊：
影响因子：
5.3
通讯作者：
Kazui, Teruhisa
中科院分区：
文献类型：
--
作者：
Takamochi, Kazuya;Suzuki, Kazuya;Kazui, Teruhisa
吉非替尼是首个被批准的表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKI），用于治疗对常规化疗无效的晚期非小细胞肺癌（NSCLC）患者。吉非替尼对含有EGFR基因突变的肿瘤患者具有相当有效的抗肿瘤活性。然而，没有关于非小细胞肺癌患者术前吉非替尼治疗的数据。我们在此报道了两例肺腺癌患者在接受吉非替尼治疗后对EGFR基因突变的残留病变进行手术切除的病例。由于我们的两名患者最初都有晚期局部肿瘤负担（大体积N2疾病），完全切除在技术上是不可行的。然而，术前吉非替尼治疗使两例患者完全切除成为可能。我们认为，需要进行临床试验来评估EGFR- tkis在EGFR基因突变的局部晚期NSCLC患者中术前治疗的作用。(c)爱思唯尔爱尔兰有限公司2007年出版
Gefitinib is the first approved epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) for the treatment of patients with advanced non-small cell lung cancer (NSCLC) who failed to respond to conventional chemotherapy. Gefitinib has fairly effective anti-tumour activity in patients with tumours harboring EGFR gene mutations. However, there has been no data about the preoperative gefitinib treatment in NSCLC patients. We reported here two cases of surgical resection of residual disease after dramatic response to gefitinib in patients with lung adenocarcinoma harboring EGFR gene mutation. Because both of our patients initially had advanced local tumour burden (bulky N2 disease), complete resection would not have been technically feasible. However, preoperative gefitinib treatment made it possible to achieve complete resection in both patients. We believe that clinical trials are required to evaluate the role of preoperative treatment of EGFR-TKIs in patients with locally advanced NSCLC harboring EGFR gene mutation. (c) 2007 Published by Elsevier Ireland Ltd.